Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of Klotho deficiency

Kidney International

Volumn 85, Issue 5, 2014, Pages 1103-1111

  Jimbo, Rika ^a   Kawakami Mori, Fumiko ^a   Mu, Shengyu ^b   Hirohama, Daigoro ^a   Majtan, Bohumil ^c   Shimizu, Yuichiro ^a   Yatomi, Yutaka ^a   Fukumoto, Seiji ^a   Fujita, Toshiro ^b   Shimosawa, Tatsuo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NONE   (Germany)

Author keywords

Chronic kidney disease; Fibroblast growth factor 23; Klotho; Phosphate; Vascular calcification

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR; KLOTHO PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATE; PHOSPHATE TRANSPORTER; BETA GLUCURONIDASE; FGF23 PROTEIN, RAT; FGFR1 PROTEIN, RAT; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE INHIBITOR; RECOMBINANT PROTEIN; SODIUM DIHYDROGEN PHOSPHATE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD VESSEL CALCIFICATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; UREMIA; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; AORTA DISEASE; CELL CULTURE; CELL DIFFERENTIATION; CHEMICALLY INDUCED; CHRONIC KIDNEY FAILURE; COMPLICATION; DEFICIENCY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; ENZYME ACTIVATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; OSTEOBLAST; PATHOLOGY; PHOSPHORYLATION; SPRAGUE DAWLEY RAT; TOXICITY;

ANIMALS; AORTA; AORTIC DISEASES; CELL DIFFERENTIATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLAST GROWTH FACTORS; GLUCURONIDASE; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; OSTEOBLASTS; PHOSPHATES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RATS, SPRAGUE-DAWLEY; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECOMBINANT PROTEINS; RENAL INSUFFICIENCY, CHRONIC; SIGNAL TRANSDUCTION; TRANSFECTION; VASCULAR CALCIFICATION;

EID: 84899737116     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.332     Document Type: Article

References (50)

1. Shanahan CM, Crouthamel MH, Kapustin A et al. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res 2011; 109: 697-711.
2. London GM, Gué rin AP, Marchais SJ et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740.
3. Jono S, McKee MD, Murry CE et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000; 87: E10-E17.
4. Li X, Yang HY, Giachelli CM. Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res 2006; 98: 905-912.
5. Adeney KL, Siscovick DS, Ix JH et al. Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol 2009; 20: 381-387.
6. Ix JH, De Boer IH, Peralta CA et al. Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA. Clin J Am Soc Nephrol 2009; 4: 609-615.
7. Villa-Bellosta R, Bogaert YE, Levi M et al. Characterization of phosphate transport in rat vascular smooth muscle cells: implications for vascular calcification. Arterioscler Thromb Vasc Biol 2007; 27: 1030-1036.
8. Fukumoto S, Yamashita T. FGF23 is a hormone-regulating phosphate metabolism-unique biological characteristics of FGF23. Bone 2007; 40: 1190-1195.
9. Gattineni J, Bates C, Twombley K et al. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor Am J Physiol Renal Physiol 2009; 297: F282-F291.
10. Hasegawa H, Nagano N, Urakawa I et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 2010; 78: 975-980.
11. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117: 4003-4008.
12. Komaba H, Goto S, Fujii H et al. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 2010; 77: 232-238.
13. Yamazaki M, Ozono K, Okada T et al. Both FGF23 and extracellular phosphate activate Raf/MEK/ERK pathway via FGF receptors in HEK293 cells. J Cell Biochem 2010; 111: 1210-1221.
14. Urakawa I, Yamazaki Y, Shimada T et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006; 444: 770-774.
15. Gutiérrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592.
16. Seiler S, Reichart B, Roth D et al. FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant 2010; 25: 3983-3989.
17. Kendrick J, Cheung AK, Kaufman JS et al. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 2011; 22: 1913-1922.
18. Jean G, Bresson E, Terrat JC et al. Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant 2009; 24: 948-955.
19. Balci M, Kirkpantur A, Gulbay M et al. Plasma fibroblast growth factor-23 levels are independently associated with carotid artery atherosclerosis in maintenance hemodialysis patients. Hemodial Int 2010; 14: 425-432.
20. Nasrallah MM, El-Shehaby AR, Salem MM et al. Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrol Dial Transplant 2010; 25: 2679-2685.
21. Donate-Correa J, Mora-Fernández C, Mart?́nez-Sanz R et al. Expression of FGF23/KLOTHO system in human vascular tissue. Int J Cardiol 2011; 165: 179-183.
22. Antoine M, Wirz W, Tag CG et al. Expression pattern of fibroblast growth factors (FGFs), their receptors and antagonists in primary endothelial cells and vascular smooth muscle cells. Growth Factors 2005; 23: 87-95.
23. Kuro-o M, Matsumura Y, Aizawa H et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390: 45-51.
24. Li SA, Watanabe M, Yamada H et al. Immunohistochemical localization of Klotho protein in brain, kidney, and reproductive organs of mice. Cell Struct Funct 2004; 29: 91-99.
25. Nakano-Kurimoto R, Ikeda K, Uraoka M et al. Replicative senescence of vascular smooth muscle cells enhances the calcification through initiating the osteoblastic transition. Am J Physiol Heart Circ Physiol 2009; 297: H1673-H1684.
26. Lim K, Lu TS, Molostvov G et al. Vascular klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor Circulation 2012; 125: 2243-2255.
27. Scialla JJ, Lau WL, Reilly MP et al. Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int 2013; 83: 1159-1168.
28. Wang H, Yoshiko Y, Yamamoto R et al. Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res 2008; 23: 939-948.
29. Bear M, Butcher M, Shaughnessy SG. Oxidized low-density lipoprotein acts synergistically with beta-glycerophosphate to induce osteoblast differentiation in primary cultures of vascular smooth muscle cells. J Cell Biochem 2008; 105: 185-193.
30. Miyazaki-Anzai S, Levi M, Kratzer A et al. Farnesoid X receptor activation prevents the development of vascular calcification in ApoE-/-mice with chronic kidney disease. Circ Res 2010; 106: 1807-1817.
31. Shao JS, Cheng SL, Pingsterhaus JM et al. Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest 2005; 115: 1210-1220.
32. Gao Y, Jheon A, Nourkeyhani H et al. Molecular cloning, structure, expression, and chromosomal localization of the human Osterix (SP7) gene. Gene 2004; 341: 101-110.
33. Taylor J, Butcher M, Zeadin M et al. Oxidized low-density lipoprotein promotes osteoblast differentiation in primary cultures of vascular smooth muscle cells by up-regulating Osterix expression in an Msx2-dependent manner. J Cell Biochem 2011; 112: 581-588.
34. Lau WL, Leaf EM, Hu MC et al. Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. Kidney Int 2012; 82: 1261-1270.
35. Galitzer H, Ben-Dov IZ, Silver J et al. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int 2010; 77: 211-218.
36. Hofman-Bang J, Martuseviciene G, Santini MA et al. Increased parathyroid expression of klotho in uremic rats. Kidney Int 2010; 78: 1119-1127.
37. Faul C, Amaral AP, Oskouei B et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393-4408.
38. Drü eke TB, Massy ZA. Role of vitamin D in vascular calcification: bad guy or good guy? Nephrol Dial Transplant 2012; 27: 1704-1707.
39. Li X, Speer MY, Yang H et al. Vitamin D receptor activators induce an anticalcific paracrine program in macrophages: requirement of osteopontin. Arterioscler Thromb Vasc Biol 2010; 30: 321-326.
40. Ding HT, Wang CG, Zhang TL et al. Fibronectin enhances in vitro vascular calcification by promoting osteoblastic differentiation of vascular smooth muscle cells via ERK pathway. J Cell Biochem 2006; 99: 1343-1352.
41. Shan PF, Lu Y, Cui RR. Apelin attenuates the osteoblastic differentiation of vascular smooth muscle cells. PLoS One 2011; 6: e17938.
42. Jabs EW, Mü ller U, Li X et al. A mutation in the homeodomain of the human MSX2 gene in a family affected with autosomal dominant craniosynostosis. Cell 1993; 75: 443-450.
43. Liu J, Shimosawa T, Matsui H et al. Adrenomedullin inhibits angiotensin IIinduced oxidative stress via Csk-mediated inhibition of Src activity. Am J Physiol Heart Circ Physiol 2007; 292: H1714-H1721.
44. Kawakami-Mori F, Shimosawa T, Mu S et al. NADPH oxidase-mediated Rac1 GTP activity is necessary for nongenomic actions of the mineralocorticoid receptor in the CA1 region of the rat hippocampus. Am J Physiol Endocrinol Metab 2012; 302: E425-E432.
45. Mu S, Shimosawa T, Ogura S et al. Epigenetic modulation of the renal badrenergic-WNK4 pathway in salt-sensitive hypertension. Nat Med 2011; 17: 573-580.
46. Tanaka T, Kojima I, Ohse T et al. Cobalt promotes angiogenesis via hypoxia-inducible factor and protects tubulointerstitium in the remnant kidney model. Lab Invest 2005; 85: 1292-1307.
47. Mune S, Shibata M, Hatamura I et al. Mechanism of phosphate-induced calcification in rat aortic tissue culture: possible involvement of Pit-1 and apoptosis. Clin Exp Nephrol 2009; 13: 571-57.
48. Son BK, Kozaki K, Iijima K et al. Statins protect human aortic smooth muscle cells from inorganic phosphate-induced calcification by restoring Gas6-Axl survival pathway. Circ Res 2006; 98: 1024-1031.
49. Yang J, Matsukawa N, Rakugi H et al. Upregulation of cAMP is a new functional signal pathway of Klotho in endothelial cells. Biochem Biophys Res Commun 2003; 301: 424-429.
50. Ikushima M, Rakugi H, Ishikawa K et al. Anti-apoptotic and antisenescence effects of Klotho on vascular endothelial cells. Biochem Biophys Res Commun 2006; 20: 827-832.